中国生物制药(01177)今日盘中大涨5%，引起了市场的广泛关注。
消息面上，公司自主研发的国家1类创新药TQB2102“HER2双抗ADC”用于治疗HER2低表达复发/转移性乳腺癌的III期临床试验，近期已完成全部受试者入组。该药物在2025年美国临床肿瘤学会年会上公布的Ib期临床研究结果已显示出良好的疗效与安全性，此次III期试验的顺利推进，增强了市场对公司创新药管线未来商业化前景的信心。
TQB2102是公司自主研发的新一代抗体偶联药物，采用了双表位靶向设计、可裂解连接子及优化的药物抗体比等核心技术，旨在为HER2低表达乳腺癌患者提供新的治疗选择。研发进度的积极消息通常是生物医药公司股价的重要催化剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.